Alzheimer's as metabolic disease
The dominant model of Alzheimer's disease has historically been amyloid-centric: amyloid-beta plaques accumulate in the brain, drive neurofibrillary tangle formation, cause neuronal death, and produce dementia. Treatments developed against this model have largely failed in trials.
An alternative or complementary view has been gaining ground: Alzheimer's involves substantial metabolic dysfunction in brain tissue. Brain glucose utilization (measured by PET imaging) drops in affected regions years before clinical symptoms. Brain insulin signaling is impaired. Inflammatory cytokines accumulate. Mitochondrial function declines. Some researchers describe Alzheimer's as "Type 3 diabetes" to highlight the metabolic component.
If metabolic dysfunction contributes to neurodegeneration, then metabolic interventions might slow it.
Brain insulin resistance
Insulin signaling in the brain regulates synaptic plasticity, learning, memory, and neuronal survival, independent of its peripheral metabolic role. Brain insulin resistance impairs all of these. Patients with Type 2 diabetes have nearly twice the risk of dementia, partly through cardiovascular mechanisms but partly through brain-specific insulin signaling failure.
Treatments that improve brain insulin signaling are therefore plausible candidates for Alzheimer's. GLP-1 therapy improves insulin signaling broadly, including in the brain.
Why GLP-1R is a target
GLP-1 receptors are expressed in:
- Hippocampus (memory)
- Cerebral cortex (cognition)
- Hypothalamus (autonomic regulation)
- Microglia (brain immune cells)
Activation in these tissues:
- Reduces neuroinflammation
- Improves neuronal insulin signaling
- Promotes synaptic plasticity
- Increases hippocampal neurogenesis (new neuron formation)
- In animal models, reduces amyloid-beta and tau accumulation
Animal study findings
In multiple Alzheimer's mouse models, GLP-1 receptor agonists:
- Reduced amyloid plaque burden
- Reduced tau hyperphosphorylation
- Improved memory and learning
- Reduced neuroinflammation
- Preserved synaptic density
- Increased hippocampal neurogenesis
Animal data is limited (mouse models don't fully recapitulate human Alzheimer's), but the consistency across models is encouraging.
Early human trials
Smaller trials with first-generation GLP-1 agonists:
- Liraglutide showed signal of preserved brain glucose metabolism and modest cognitive benefit in early Alzheimer's patients
- Exenatide trials in Parkinson's disease (related neurodegenerative pathway) showed motor and cognitive improvements
- Type 2 diabetes patients on GLP-1 therapy show small cognitive benefits in some studies
None of these were definitive. They motivated larger trials.
EVOKE and EVOKE+
The EVOKE and EVOKE+ trials of semaglutide in early-stage Alzheimer's disease randomized roughly 3,500 patients across both trials to oral semaglutide or placebo for 2+ years. Primary endpoint: cognitive decline as measured by Clinical Dementia Rating Scale.
Expected readout: 2026. Results will determine whether semaglutide becomes a recognized Alzheimer's treatment. If positive, the implications would be substantial, the first metabolic intervention shown to slow neurodegeneration.
Implications
For patients on GLP-1 therapy currently for metabolic indications, any cognitive benefit (if real) is essentially a bonus on top of metabolic improvement. The medication is not currently indicated for Alzheimer's prevention or treatment outside trials. Whether it should be considered for high-risk patients depends on EVOKE results.
Even before trial readout, the rationale for GLP-1 therapy in patients with metabolic risk factors and family history of Alzheimer's is strengthening.
The clinical pearl: If EVOKE reads positive, GLP-1 therapy will be the first metabolic intervention shown to slow Alzheimer's progression. If it reads neutral or negative, the field continues but with less momentum. Either way, the biological rationale, receptor expression in vulnerable brain regions, anti-inflammatory effects, improved insulin signaling, is solid.
Bottom line
GLP-1 therapy is being tested in Alzheimer's disease based on biological rationale (brain GLP-1R expression, anti-inflammatory effects, improved insulin signaling, animal model benefits) and early trial signals. EVOKE trial results expected in 2026 will determine whether this becomes a recognized indication. For patients on therapy now for metabolic reasons, cognitive benefit is plausible but not yet established.